Persistent insulin drug product shortages
DP shortages continue, causing a 20% gap in supply; management noted a ₹10 crore revenue hit in Q1 and a strategic stockpile increased working capital by ₹73 crore.
high · management_commentary
Eris Lifesciences Ltd — Q3 FY26
Eris Lifesciences reported Q1 FY26 consolidated revenue of ₹773 crore (+7.4% YoY) and PAT of ₹125 crore (+41% YoY), driven by strong domestic branded business (DBS) growth of 11...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Capacity constraints in injectables for 1.5-2 years
Management acknowledged capacity constraints in a couple of lines, limiting volume growth until new unit is commissioned, which may take 1.5-2 years.
medium · analyst_questionGLP-1 market formation delay or competition
Liraglutide (LRA) ramp-up slower than expected due to stiff competition and delayed obesity approval for generic exenatide; management lowered near-term expectations.
medium · analyst_questionTrade generics ramp-down impact on revenue
Trade generics revenue fell from ₹13 crore to ₹3 crore YoY; full-year impact could be ~₹40 crore revenue loss, though it was never profitable.
low · data_observation